nodes	percent_of_prediction	percent_of_DWPC	metapath
Degarelix—GNRHR—GPCRs, Other—GRM8—lung cancer	0.0028	0.0591	CbGpPWpGaD
Degarelix—GNRHR—Peptide GPCRs—OXTR—lung cancer	0.00272	0.0574	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GRP—lung cancer	0.0013	0.0274	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—OXTR—lung cancer	0.0013	0.0274	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—GNG11—lung cancer	0.00121	0.0256	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GRP—lung cancer	0.00116	0.0245	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—OXTR—lung cancer	0.00116	0.0245	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GNG11—lung cancer	0.00109	0.0229	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—ANXA1—lung cancer	0.000954	0.0201	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GIPR—lung cancer	0.000934	0.0197	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—APP—lung cancer	0.000904	0.0191	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—OXTR—lung cancer	0.000858	0.0181	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—GRP—lung cancer	0.000858	0.0181	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—ANXA1—lung cancer	0.000853	0.018	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—APP—lung cancer	0.000808	0.0171	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GRM8—lung cancer	0.000794	0.0168	CbGpPWpGaD
Degarelix—GNRHR—G alpha (q) signalling events—AVP—lung cancer	0.000703	0.0148	CbGpPWpGaD
Degarelix—Nausea—Erlotinib—lung cancer	0.000673	0.000707	CcSEcCtD
Degarelix—Dry mouth—Paclitaxel—lung cancer	0.000672	0.000706	CcSEcCtD
Degarelix—Anaphylactic shock—Etoposide—lung cancer	0.000672	0.000706	CcSEcCtD
Degarelix—Diarrhoea—Vinorelbine—lung cancer	0.000671	0.000704	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Cisplatin—lung cancer	0.000669	0.000702	CcSEcCtD
Degarelix—Feeling abnormal—Irinotecan—lung cancer	0.000666	0.000699	CcSEcCtD
Degarelix—Back pain—Docetaxel—lung cancer	0.000662	0.000695	CcSEcCtD
Degarelix—Dysuria—Methotrexate—lung cancer	0.000662	0.000695	CcSEcCtD
Degarelix—Gastrointestinal pain—Irinotecan—lung cancer	0.000661	0.000694	CcSEcCtD
Degarelix—Anaphylactic shock—Paclitaxel—lung cancer	0.000659	0.000692	CcSEcCtD
Degarelix—Muscle spasms—Docetaxel—lung cancer	0.000658	0.000691	CcSEcCtD
Degarelix—Dyspnoea—Cisplatin—lung cancer	0.000654	0.000687	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—OXTR—lung cancer	0.000654	0.0138	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—GRP—lung cancer	0.000654	0.0138	CbGpPWpGaD
Degarelix—Skin disorder—Etoposide—lung cancer	0.000653	0.000685	CcSEcCtD
Degarelix—Erectile dysfunction—Methotrexate—lung cancer	0.000652	0.000685	CcSEcCtD
Degarelix—Hyperhidrosis—Etoposide—lung cancer	0.00065	0.000682	CcSEcCtD
Degarelix—Feeling abnormal—Gemcitabine—lung cancer	0.000649	0.000681	CcSEcCtD
Degarelix—Dizziness—Vinorelbine—lung cancer	0.000648	0.00068	CcSEcCtD
Degarelix—Nervous system disorder—Paclitaxel—lung cancer	0.000646	0.000679	CcSEcCtD
Degarelix—Breast disorder—Doxorubicin—lung cancer	0.000641	0.000673	CcSEcCtD
Degarelix—Skin disorder—Paclitaxel—lung cancer	0.00064	0.000672	CcSEcCtD
Degarelix—Abdominal pain—Irinotecan—lung cancer	0.000639	0.000671	CcSEcCtD
Degarelix—Body temperature increased—Irinotecan—lung cancer	0.000639	0.000671	CcSEcCtD
Degarelix—Decreased appetite—Cisplatin—lung cancer	0.000638	0.00067	CcSEcCtD
Degarelix—Hyperhidrosis—Paclitaxel—lung cancer	0.000637	0.000669	CcSEcCtD
Degarelix—Gastrointestinal disorder—Cisplatin—lung cancer	0.000634	0.000665	CcSEcCtD
Degarelix—Anaemia—Docetaxel—lung cancer	0.000633	0.000664	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—ANXA1—lung cancer	0.000632	0.0133	CbGpPWpGaD
Degarelix—Depression—Methotrexate—lung cancer	0.00063	0.000661	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AVP—lung cancer	0.000629	0.0133	CbGpPWpGaD
Degarelix—Hypotension—Etoposide—lung cancer	0.000628	0.000659	CcSEcCtD
Degarelix—Pain—Cisplatin—lung cancer	0.000628	0.000659	CcSEcCtD
Degarelix—Muscular weakness—Doxorubicin—lung cancer	0.000626	0.000657	CcSEcCtD
Degarelix—Vomiting—Vinorelbine—lung cancer	0.000623	0.000654	CcSEcCtD
Degarelix—Body temperature increased—Gemcitabine—lung cancer	0.000622	0.000653	CcSEcCtD
Degarelix—Renal failure—Methotrexate—lung cancer	0.000621	0.000652	CcSEcCtD
Degarelix—Rash—Vinorelbine—lung cancer	0.000618	0.000649	CcSEcCtD
Degarelix—Dermatitis—Vinorelbine—lung cancer	0.000617	0.000648	CcSEcCtD
Degarelix—Hypotension—Paclitaxel—lung cancer	0.000616	0.000647	CcSEcCtD
Degarelix—Headache—Vinorelbine—lung cancer	0.000614	0.000644	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—GNG11—lung cancer	0.000612	0.0129	CbGpPWpGaD
Degarelix—Palpitations—Docetaxel—lung cancer	0.000605	0.000635	CcSEcCtD
Degarelix—Feeling abnormal—Cisplatin—lung cancer	0.000605	0.000635	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Paclitaxel—lung cancer	0.000601	0.00063	CcSEcCtD
Degarelix—Dyspnoea—Etoposide—lung cancer	0.000599	0.000629	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—APP—lung cancer	0.000599	0.0126	CbGpPWpGaD
Degarelix—Hepatobiliary disease—Methotrexate—lung cancer	0.000597	0.000627	CcSEcCtD
Degarelix—Insomnia—Paclitaxel—lung cancer	0.000596	0.000626	CcSEcCtD
Degarelix—Hypersensitivity—Irinotecan—lung cancer	0.000595	0.000625	CcSEcCtD
Degarelix—Hypertension—Docetaxel—lung cancer	0.000591	0.00062	CcSEcCtD
Degarelix—Dyspnoea—Paclitaxel—lung cancer	0.000588	0.000617	CcSEcCtD
Degarelix—Decreased appetite—Etoposide—lung cancer	0.000584	0.000613	CcSEcCtD
Degarelix—Arthralgia—Docetaxel—lung cancer	0.000583	0.000612	CcSEcCtD
Degarelix—Nausea—Vinorelbine—lung cancer	0.000582	0.000611	CcSEcCtD
Degarelix—Gastrointestinal disorder—Etoposide—lung cancer	0.00058	0.000609	CcSEcCtD
Degarelix—Body temperature increased—Cisplatin—lung cancer	0.00058	0.000609	CcSEcCtD
Degarelix—Asthenia—Irinotecan—lung cancer	0.00058	0.000609	CcSEcCtD
Degarelix—Fatigue—Etoposide—lung cancer	0.00058	0.000608	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—lung cancer	0.000579	0.000608	CcSEcCtD
Degarelix—Pain—Etoposide—lung cancer	0.000575	0.000603	CcSEcCtD
Degarelix—Constipation—Etoposide—lung cancer	0.000575	0.000603	CcSEcCtD
Degarelix—Dysuria—Doxorubicin—lung cancer	0.000573	0.000602	CcSEcCtD
Degarelix—Decreased appetite—Paclitaxel—lung cancer	0.000573	0.000601	CcSEcCtD
Degarelix—Dry mouth—Docetaxel—lung cancer	0.00057	0.000598	CcSEcCtD
Degarelix—Gastrointestinal disorder—Paclitaxel—lung cancer	0.000569	0.000597	CcSEcCtD
Degarelix—Fatigue—Paclitaxel—lung cancer	0.000568	0.000597	CcSEcCtD
Degarelix—Pollakiuria—Doxorubicin—lung cancer	0.000566	0.000595	CcSEcCtD
Degarelix—Asthenia—Gemcitabine—lung cancer	0.000565	0.000593	CcSEcCtD
Degarelix—Constipation—Paclitaxel—lung cancer	0.000564	0.000592	CcSEcCtD
Degarelix—Pain—Paclitaxel—lung cancer	0.000564	0.000592	CcSEcCtD
Degarelix—Urinary tract disorder—Methotrexate—lung cancer	0.00056	0.000588	CcSEcCtD
Degarelix—Anaphylactic shock—Docetaxel—lung cancer	0.000559	0.000586	CcSEcCtD
Degarelix—Weight increased—Doxorubicin—lung cancer	0.000558	0.000586	CcSEcCtD
Degarelix—Pruritus—Gemcitabine—lung cancer	0.000557	0.000585	CcSEcCtD
Degarelix—Urethral disorder—Methotrexate—lung cancer	0.000556	0.000583	CcSEcCtD
Degarelix—Weight decreased—Doxorubicin—lung cancer	0.000555	0.000582	CcSEcCtD
Degarelix—Feeling abnormal—Etoposide—lung cancer	0.000554	0.000582	CcSEcCtD
Degarelix—Hyperglycaemia—Doxorubicin—lung cancer	0.000553	0.000581	CcSEcCtD
Degarelix—Diarrhoea—Irinotecan—lung cancer	0.000553	0.00058	CcSEcCtD
Degarelix—Gastrointestinal pain—Etoposide—lung cancer	0.00055	0.000577	CcSEcCtD
Degarelix—Nervous system disorder—Docetaxel—lung cancer	0.000548	0.000575	CcSEcCtD
Degarelix—Feeling abnormal—Paclitaxel—lung cancer	0.000543	0.00057	CcSEcCtD
Degarelix—Skin disorder—Docetaxel—lung cancer	0.000543	0.00057	CcSEcCtD
Degarelix—Hypersensitivity—Cisplatin—lung cancer	0.000541	0.000568	CcSEcCtD
Degarelix—Gastrointestinal pain—Paclitaxel—lung cancer	0.000539	0.000566	CcSEcCtD
Degarelix—Diarrhoea—Gemcitabine—lung cancer	0.000539	0.000565	CcSEcCtD
Degarelix—Renal failure—Doxorubicin—lung cancer	0.000537	0.000564	CcSEcCtD
Degarelix—Dizziness—Irinotecan—lung cancer	0.000534	0.000561	CcSEcCtD
Degarelix—Urticaria—Etoposide—lung cancer	0.000534	0.000561	CcSEcCtD
Degarelix—Abdominal pain—Etoposide—lung cancer	0.000531	0.000558	CcSEcCtD
Degarelix—Body temperature increased—Etoposide—lung cancer	0.000531	0.000558	CcSEcCtD
Degarelix—Urinary tract infection—Doxorubicin—lung cancer	0.000531	0.000558	CcSEcCtD
Degarelix—Eye disorder—Methotrexate—lung cancer	0.00053	0.000556	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GIPR—lung cancer	0.000528	0.0111	CbGpPWpGaD
Degarelix—Asthenia—Cisplatin—lung cancer	0.000526	0.000553	CcSEcCtD
Degarelix—Cardiac disorder—Methotrexate—lung cancer	0.000526	0.000552	CcSEcCtD
Degarelix—Urticaria—Paclitaxel—lung cancer	0.000524	0.00055	CcSEcCtD
Degarelix—Hypotension—Docetaxel—lung cancer	0.000522	0.000548	CcSEcCtD
Degarelix—Body temperature increased—Paclitaxel—lung cancer	0.000521	0.000547	CcSEcCtD
Degarelix—Abdominal pain—Paclitaxel—lung cancer	0.000521	0.000547	CcSEcCtD
Degarelix—Hepatobiliary disease—Doxorubicin—lung cancer	0.000517	0.000543	CcSEcCtD
Degarelix—Angiopathy—Methotrexate—lung cancer	0.000514	0.00054	CcSEcCtD
Degarelix—Vomiting—Irinotecan—lung cancer	0.000514	0.000539	CcSEcCtD
Degarelix—Immune system disorder—Methotrexate—lung cancer	0.000512	0.000537	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—PTHLH—lung cancer	0.000511	0.0108	CbGpPWpGaD
Degarelix—Mediastinal disorder—Methotrexate—lung cancer	0.000511	0.000536	CcSEcCtD
Degarelix—Rash—Irinotecan—lung cancer	0.00051	0.000535	CcSEcCtD
Degarelix—Dermatitis—Irinotecan—lung cancer	0.000509	0.000534	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Docetaxel—lung cancer	0.000509	0.000534	CcSEcCtD
Degarelix—Chills—Methotrexate—lung cancer	0.000509	0.000534	CcSEcCtD
Degarelix—Headache—Irinotecan—lung cancer	0.000506	0.000532	CcSEcCtD
Degarelix—Insomnia—Docetaxel—lung cancer	0.000505	0.00053	CcSEcCtD
Degarelix—Diarrhoea—Cisplatin—lung cancer	0.000502	0.000527	CcSEcCtD
Degarelix—Alopecia—Methotrexate—lung cancer	0.000501	0.000526	CcSEcCtD
Degarelix—Vomiting—Gemcitabine—lung cancer	0.000501	0.000525	CcSEcCtD
Degarelix—Dyspnoea—Docetaxel—lung cancer	0.000498	0.000523	CcSEcCtD
Degarelix—Mental disorder—Methotrexate—lung cancer	0.000497	0.000521	CcSEcCtD
Degarelix—Rash—Gemcitabine—lung cancer	0.000496	0.000521	CcSEcCtD
Degarelix—Dermatitis—Gemcitabine—lung cancer	0.000496	0.000521	CcSEcCtD
Degarelix—Hypersensitivity—Etoposide—lung cancer	0.000495	0.00052	CcSEcCtD
Degarelix—Erythema—Methotrexate—lung cancer	0.000493	0.000518	CcSEcCtD
Degarelix—Malnutrition—Methotrexate—lung cancer	0.000493	0.000518	CcSEcCtD
Degarelix—Headache—Gemcitabine—lung cancer	0.000493	0.000518	CcSEcCtD
Degarelix—Hypoaesthesia—Doxorubicin—lung cancer	0.000488	0.000513	CcSEcCtD
Degarelix—Decreased appetite—Docetaxel—lung cancer	0.000486	0.00051	CcSEcCtD
Degarelix—Hypersensitivity—Paclitaxel—lung cancer	0.000486	0.00051	CcSEcCtD
Degarelix—Urinary tract disorder—Doxorubicin—lung cancer	0.000485	0.000509	CcSEcCtD
Degarelix—Oedema peripheral—Doxorubicin—lung cancer	0.000483	0.000508	CcSEcCtD
Degarelix—Gastrointestinal disorder—Docetaxel—lung cancer	0.000482	0.000506	CcSEcCtD
Degarelix—Asthenia—Etoposide—lung cancer	0.000482	0.000506	CcSEcCtD
Degarelix—Fatigue—Docetaxel—lung cancer	0.000482	0.000506	CcSEcCtD
Degarelix—Urethral disorder—Doxorubicin—lung cancer	0.000481	0.000505	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—ANXA1—lung cancer	0.000481	0.0101	CbGpPWpGaD
Degarelix—Nausea—Irinotecan—lung cancer	0.00048	0.000504	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—GIPR—lung cancer	0.000479	0.0101	CbGpPWpGaD
Degarelix—Constipation—Docetaxel—lung cancer	0.000478	0.000502	CcSEcCtD
Degarelix—Pain—Docetaxel—lung cancer	0.000478	0.000502	CcSEcCtD
Degarelix—Back pain—Methotrexate—lung cancer	0.000477	0.000501	CcSEcCtD
Degarelix—Pruritus—Etoposide—lung cancer	0.000476	0.000499	CcSEcCtD
Degarelix—Asthenia—Paclitaxel—lung cancer	0.000473	0.000496	CcSEcCtD
Degarelix—Nausea—Gemcitabine—lung cancer	0.000468	0.000491	CcSEcCtD
Degarelix—Vomiting—Cisplatin—lung cancer	0.000467	0.00049	CcSEcCtD
Degarelix—Pruritus—Paclitaxel—lung cancer	0.000466	0.00049	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—AVP—lung cancer	0.000466	0.00983	CbGpPWpGaD
Degarelix—Vision blurred—Methotrexate—lung cancer	0.000465	0.000488	CcSEcCtD
Degarelix—Rash—Cisplatin—lung cancer	0.000463	0.000486	CcSEcCtD
Degarelix—Dermatitis—Cisplatin—lung cancer	0.000462	0.000485	CcSEcCtD
Degarelix—Feeling abnormal—Docetaxel—lung cancer	0.00046	0.000483	CcSEcCtD
Degarelix—Diarrhoea—Etoposide—lung cancer	0.00046	0.000483	CcSEcCtD
Degarelix—Eye disorder—Doxorubicin—lung cancer	0.000459	0.000481	CcSEcCtD
Degarelix—Ill-defined disorder—Methotrexate—lung cancer	0.000458	0.000481	CcSEcCtD
Degarelix—Gastrointestinal pain—Docetaxel—lung cancer	0.000457	0.00048	CcSEcCtD
Degarelix—Anaemia—Methotrexate—lung cancer	0.000456	0.000479	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—APP—lung cancer	0.000456	0.00962	CbGpPWpGaD
Degarelix—Cardiac disorder—Doxorubicin—lung cancer	0.000455	0.000478	CcSEcCtD
Degarelix—Diarrhoea—Paclitaxel—lung cancer	0.000451	0.000473	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GRM8—lung cancer	0.000449	0.00947	CbGpPWpGaD
Degarelix—Angiopathy—Doxorubicin—lung cancer	0.000445	0.000467	CcSEcCtD
Degarelix—Malaise—Methotrexate—lung cancer	0.000445	0.000467	CcSEcCtD
Degarelix—Dizziness—Etoposide—lung cancer	0.000445	0.000467	CcSEcCtD
Degarelix—Immune system disorder—Doxorubicin—lung cancer	0.000443	0.000465	CcSEcCtD
Degarelix—Mediastinal disorder—Doxorubicin—lung cancer	0.000442	0.000464	CcSEcCtD
Degarelix—Abdominal pain—Docetaxel—lung cancer	0.000442	0.000464	CcSEcCtD
Degarelix—Body temperature increased—Docetaxel—lung cancer	0.000442	0.000464	CcSEcCtD
Degarelix—Chills—Doxorubicin—lung cancer	0.00044	0.000462	CcSEcCtD
Degarelix—Arrhythmia—Doxorubicin—lung cancer	0.000438	0.00046	CcSEcCtD
Degarelix—Dizziness—Paclitaxel—lung cancer	0.000436	0.000458	CcSEcCtD
Degarelix—Nausea—Cisplatin—lung cancer	0.000436	0.000458	CcSEcCtD
Degarelix—Alopecia—Doxorubicin—lung cancer	0.000434	0.000455	CcSEcCtD
Degarelix—Mental disorder—Doxorubicin—lung cancer	0.00043	0.000451	CcSEcCtD
Degarelix—Vomiting—Etoposide—lung cancer	0.000427	0.000449	CcSEcCtD
Degarelix—Erythema—Doxorubicin—lung cancer	0.000427	0.000448	CcSEcCtD
Degarelix—Malnutrition—Doxorubicin—lung cancer	0.000427	0.000448	CcSEcCtD
Degarelix—Rash—Etoposide—lung cancer	0.000424	0.000445	CcSEcCtD
Degarelix—Dermatitis—Etoposide—lung cancer	0.000423	0.000445	CcSEcCtD
Degarelix—Headache—Etoposide—lung cancer	0.000421	0.000442	CcSEcCtD
Degarelix—Arthralgia—Methotrexate—lung cancer	0.00042	0.000441	CcSEcCtD
Degarelix—Vomiting—Paclitaxel—lung cancer	0.000419	0.00044	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lung cancer	0.000417	0.000438	CcSEcCtD
Degarelix—Rash—Paclitaxel—lung cancer	0.000416	0.000436	CcSEcCtD
Degarelix—Dermatitis—Paclitaxel—lung cancer	0.000415	0.000436	CcSEcCtD
Degarelix—Discomfort—Methotrexate—lung cancer	0.000415	0.000436	CcSEcCtD
Degarelix—Back pain—Doxorubicin—lung cancer	0.000413	0.000434	CcSEcCtD
Degarelix—Headache—Paclitaxel—lung cancer	0.000413	0.000433	CcSEcCtD
Degarelix—Hypersensitivity—Docetaxel—lung cancer	0.000412	0.000432	CcSEcCtD
Degarelix—Muscle spasms—Doxorubicin—lung cancer	0.000411	0.000431	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6R—lung cancer	0.000408	0.0086	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—GRM8—lung cancer	0.000407	0.0086	CbGpPWpGaD
Degarelix—Anaphylactic shock—Methotrexate—lung cancer	0.000403	0.000423	CcSEcCtD
Degarelix—Vision blurred—Doxorubicin—lung cancer	0.000403	0.000423	CcSEcCtD
Degarelix—Asthenia—Docetaxel—lung cancer	0.000401	0.000421	CcSEcCtD
Degarelix—Nausea—Etoposide—lung cancer	0.000399	0.000419	CcSEcCtD
Degarelix—Ill-defined disorder—Doxorubicin—lung cancer	0.000396	0.000416	CcSEcCtD
Degarelix—Pruritus—Docetaxel—lung cancer	0.000395	0.000415	CcSEcCtD
Degarelix—Nervous system disorder—Methotrexate—lung cancer	0.000395	0.000415	CcSEcCtD
Degarelix—Anaemia—Doxorubicin—lung cancer	0.000395	0.000415	CcSEcCtD
Degarelix—Nausea—Paclitaxel—lung cancer	0.000392	0.000411	CcSEcCtD
Degarelix—Skin disorder—Methotrexate—lung cancer	0.000391	0.000411	CcSEcCtD
Degarelix—Hyperhidrosis—Methotrexate—lung cancer	0.000389	0.000409	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAP2K1—lung cancer	0.000388	0.0082	CbGpPWpGaD
Degarelix—Malaise—Doxorubicin—lung cancer	0.000385	0.000404	CcSEcCtD
Degarelix—Diarrhoea—Docetaxel—lung cancer	0.000382	0.000401	CcSEcCtD
Degarelix—Palpitations—Doxorubicin—lung cancer	0.000378	0.000396	CcSEcCtD
Degarelix—Hypotension—Methotrexate—lung cancer	0.000376	0.000395	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—AXL—lung cancer	0.000373	0.00788	CbGpPWpGaD
Degarelix—Dizziness—Docetaxel—lung cancer	0.000369	0.000388	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—OXTR—lung cancer	0.000369	0.0078	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—GRP—lung cancer	0.000369	0.0078	CbGpPWpGaD
Degarelix—Hypertension—Doxorubicin—lung cancer	0.000369	0.000387	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Methotrexate—lung cancer	0.000367	0.000385	CcSEcCtD
Degarelix—Insomnia—Methotrexate—lung cancer	0.000364	0.000382	CcSEcCtD
Degarelix—Arthralgia—Doxorubicin—lung cancer	0.000364	0.000382	CcSEcCtD
Degarelix—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—lung cancer	0.000361	0.000379	CcSEcCtD
Degarelix—Discomfort—Doxorubicin—lung cancer	0.000359	0.000377	CcSEcCtD
Degarelix—Dyspnoea—Methotrexate—lung cancer	0.000359	0.000377	CcSEcCtD
Degarelix—Dry mouth—Doxorubicin—lung cancer	0.000356	0.000373	CcSEcCtD
Degarelix—Vomiting—Docetaxel—lung cancer	0.000355	0.000373	CcSEcCtD
Degarelix—GNRHR—GPCR ligand binding—AVP—lung cancer	0.000355	0.00748	CbGpPWpGaD
Degarelix—Rash—Docetaxel—lung cancer	0.000352	0.00037	CcSEcCtD
Degarelix—Dermatitis—Docetaxel—lung cancer	0.000352	0.000369	CcSEcCtD
Degarelix—Decreased appetite—Methotrexate—lung cancer	0.00035	0.000367	CcSEcCtD
Degarelix—Headache—Docetaxel—lung cancer	0.00035	0.000367	CcSEcCtD
Degarelix—Anaphylactic shock—Doxorubicin—lung cancer	0.000349	0.000366	CcSEcCtD
Degarelix—Gastrointestinal disorder—Methotrexate—lung cancer	0.000348	0.000365	CcSEcCtD
Degarelix—Fatigue—Methotrexate—lung cancer	0.000347	0.000364	CcSEcCtD
Degarelix—GNRHR—GPCR downstream signaling—GNG11—lung cancer	0.000346	0.0073	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—lung cancer	0.000345	0.00727	CbGpPWpGaD
Degarelix—Pain—Methotrexate—lung cancer	0.000344	0.000361	CcSEcCtD
Degarelix—Nervous system disorder—Doxorubicin—lung cancer	0.000342	0.000359	CcSEcCtD
Degarelix—Skin disorder—Doxorubicin—lung cancer	0.000339	0.000356	CcSEcCtD
Degarelix—Hyperhidrosis—Doxorubicin—lung cancer	0.000337	0.000354	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—GRP—lung cancer	0.000335	0.00708	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—OXTR—lung cancer	0.000335	0.00708	CbGpPWpGaD
Degarelix—Nausea—Docetaxel—lung cancer	0.000332	0.000348	CcSEcCtD
Degarelix—Feeling abnormal—Methotrexate—lung cancer	0.000332	0.000348	CcSEcCtD
Degarelix—Gastrointestinal pain—Methotrexate—lung cancer	0.000329	0.000346	CcSEcCtD
Degarelix—Hypotension—Doxorubicin—lung cancer	0.000326	0.000342	CcSEcCtD
Degarelix—Urticaria—Methotrexate—lung cancer	0.00032	0.000336	CcSEcCtD
Degarelix—Body temperature increased—Methotrexate—lung cancer	0.000318	0.000334	CcSEcCtD
Degarelix—Abdominal pain—Methotrexate—lung cancer	0.000318	0.000334	CcSEcCtD
Degarelix—Musculoskeletal discomfort—Doxorubicin—lung cancer	0.000318	0.000333	CcSEcCtD
Degarelix—Insomnia—Doxorubicin—lung cancer	0.000315	0.000331	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—GNG11—lung cancer	0.000314	0.00663	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ADCY1—lung cancer	0.000311	0.00656	CbGpPWpGaD
Degarelix—Dyspnoea—Doxorubicin—lung cancer	0.000311	0.000326	CcSEcCtD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—POMC—lung cancer	0.000309	0.00653	CbGpPWpGaD
Degarelix—Decreased appetite—Doxorubicin—lung cancer	0.000303	0.000318	CcSEcCtD
Degarelix—Gastrointestinal disorder—Doxorubicin—lung cancer	0.000301	0.000316	CcSEcCtD
Degarelix—Fatigue—Doxorubicin—lung cancer	0.000301	0.000316	CcSEcCtD
Degarelix—Pain—Doxorubicin—lung cancer	0.000298	0.000313	CcSEcCtD
Degarelix—Constipation—Doxorubicin—lung cancer	0.000298	0.000313	CcSEcCtD
Degarelix—Hypersensitivity—Methotrexate—lung cancer	0.000297	0.000311	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—COL4A2—lung cancer	0.00029	0.00613	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PTHLH—lung cancer	0.000289	0.0061	CbGpPWpGaD
Degarelix—Asthenia—Methotrexate—lung cancer	0.000289	0.000303	CcSEcCtD
Degarelix—Feeling abnormal—Doxorubicin—lung cancer	0.000287	0.000302	CcSEcCtD
Degarelix—Gastrointestinal pain—Doxorubicin—lung cancer	0.000285	0.000299	CcSEcCtD
Degarelix—Pruritus—Methotrexate—lung cancer	0.000285	0.000299	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GIPR—lung cancer	0.000283	0.00597	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ADCY1—lung cancer	0.000282	0.00596	CbGpPWpGaD
Degarelix—Urticaria—Doxorubicin—lung cancer	0.000277	0.000291	CcSEcCtD
Degarelix—Body temperature increased—Doxorubicin—lung cancer	0.000276	0.000289	CcSEcCtD
Degarelix—Abdominal pain—Doxorubicin—lung cancer	0.000276	0.000289	CcSEcCtD
Degarelix—Diarrhoea—Methotrexate—lung cancer	0.000276	0.000289	CcSEcCtD
Degarelix—GNRHR—Signaling by GPCR—PPP2R1B—lung cancer	0.000275	0.00581	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—ANXA1—lung cancer	0.000272	0.00574	CbGpPWpGaD
Degarelix—Dizziness—Methotrexate—lung cancer	0.000266	0.00028	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—SDC4—lung cancer	0.000264	0.00558	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PTHLH—lung cancer	0.000262	0.00554	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—lung cancer	0.000259	0.00547	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—DUSP3—lung cancer	0.000259	0.00546	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—APP—lung cancer	0.000258	0.00544	CbGpPWpGaD
Degarelix—Hypersensitivity—Doxorubicin—lung cancer	0.000257	0.00027	CcSEcCtD
Degarelix—Vomiting—Methotrexate—lung cancer	0.000256	0.000269	CcSEcCtD
Degarelix—Rash—Methotrexate—lung cancer	0.000254	0.000267	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—RHEB—lung cancer	0.000254	0.00536	CbGpPWpGaD
Degarelix—Dermatitis—Methotrexate—lung cancer	0.000254	0.000266	CcSEcCtD
Degarelix—Headache—Methotrexate—lung cancer	0.000252	0.000265	CcSEcCtD
Degarelix—Asthenia—Doxorubicin—lung cancer	0.00025	0.000263	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—lung cancer	0.000248	0.00524	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—ANXA1—lung cancer	0.000247	0.00521	CbGpPWpGaD
Degarelix—Pruritus—Doxorubicin—lung cancer	0.000247	0.000259	CcSEcCtD
Degarelix—GNRHR—Signaling Pathways—GRM8—lung cancer	0.000241	0.00508	CbGpPWpGaD
Degarelix—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—lung cancer	0.000239	0.00505	CbGpPWpGaD
Degarelix—Nausea—Methotrexate—lung cancer	0.000239	0.000251	CcSEcCtD
Degarelix—Diarrhoea—Doxorubicin—lung cancer	0.000239	0.00025	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—lung cancer	0.000236	0.00499	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—POMC—lung cancer	0.000236	0.00497	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—APP—lung cancer	0.000234	0.00494	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SKI—lung cancer	0.000233	0.00492	CbGpPWpGaD
Degarelix—Dizziness—Doxorubicin—lung cancer	0.000231	0.000242	CcSEcCtD
Degarelix—GNRHR—G alpha (q) signalling events—PIK3CA—lung cancer	0.000229	0.00484	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—lung cancer	0.000223	0.00471	CbGpPWpGaD
Degarelix—Vomiting—Doxorubicin—lung cancer	0.000222	0.000233	CcSEcCtD
Degarelix—Rash—Doxorubicin—lung cancer	0.00022	0.000231	CcSEcCtD
Degarelix—Dermatitis—Doxorubicin—lung cancer	0.00022	0.000231	CcSEcCtD
Degarelix—Headache—Doxorubicin—lung cancer	0.000218	0.000229	CcSEcCtD
Degarelix—Nausea—Doxorubicin—lung cancer	0.000207	0.000217	CcSEcCtD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—lung cancer	0.000205	0.00433	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PXN—lung cancer	0.000202	0.00427	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AVP—lung cancer	0.0002	0.00423	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKR1C1—lung cancer	0.000198	0.00418	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—OXTR—lung cancer	0.000198	0.00418	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GRP—lung cancer	0.000198	0.00418	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—lung cancer	0.00019	0.004	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—GNG11—lung cancer	0.000185	0.00391	CbGpPWpGaD
Degarelix—GNRHR—GPCR ligand binding—CXCL8—lung cancer	0.000182	0.00385	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AVP—lung cancer	0.000182	0.00384	CbGpPWpGaD
Degarelix—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—lung cancer	0.000182	0.00383	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFC—lung cancer	0.000177	0.00373	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ADCY1—lung cancer	0.000167	0.00352	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SMARCA4—lung cancer	0.000163	0.00343	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PPP2R1B—lung cancer	0.000163	0.00343	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HSPB1—lung cancer	0.000157	0.00331	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTHLH—lung cancer	0.000155	0.00327	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ANXA1—lung cancer	0.000146	0.00308	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FLT1—lung cancer	0.000141	0.00298	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CG—lung cancer	0.00014	0.00295	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NOTCH3—lung cancer	0.000138	0.00292	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APP—lung cancer	0.000138	0.00292	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGF9—lung cancer	0.000137	0.00289	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—POMC—lung cancer	0.000133	0.00281	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JUNB—lung cancer	0.000131	0.00276	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CG—lung cancer	0.000127	0.00268	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CD—lung cancer	0.000123	0.0026	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—POMC—lung cancer	0.000121	0.00255	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STK11—lung cancer	0.000119	0.00251	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6R—lung cancer	0.000118	0.00249	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FOXO3—lung cancer	0.000115	0.00242	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAP2K1—lung cancer	0.000112	0.00237	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CD—lung cancer	0.000112	0.00236	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AVP—lung cancer	0.000107	0.00227	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CB—lung cancer	0.000107	0.00226	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IGF1R—lung cancer	0.000103	0.00218	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—CXCL8—lung cancer	0.000103	0.00217	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HES1—lung cancer	0.000102	0.00214	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—RAF1—lung cancer	9.97e-05	0.0021	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—IL2—lung cancer	9.84e-05	0.00208	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CB—lung cancer	9.73e-05	0.00205	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—CXCL8—lung cancer	9.35e-05	0.00197	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB3—lung cancer	9.29e-05	0.00196	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL2—lung cancer	8.94e-05	0.00189	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TERT—lung cancer	8.91e-05	0.00188	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—FGFR1—lung cancer	8.65e-05	0.00183	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HIF1A—lung cancer	8.52e-05	0.0018	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APOA1—lung cancer	8.22e-05	0.00173	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KDR—lung cancer	8.15e-05	0.00172	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—APC—lung cancer	7.5e-05	0.00158	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KIT—lung cancer	7.5e-05	0.00158	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CG—lung cancer	7.5e-05	0.00158	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—NRAS—lung cancer	7.5e-05	0.00158	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGF—lung cancer	7.42e-05	0.00157	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—MAPK3—lung cancer	7.19e-05	0.00152	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—POMC—lung cancer	7.14e-05	0.00151	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—BRAF—lung cancer	7.05e-05	0.00149	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6R—lung cancer	6.97e-05	0.00147	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CREBBP—lung cancer	6.96e-05	0.00147	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—EGFR—lung cancer	6.84e-05	0.00144	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAP2K1—lung cancer	6.64e-05	0.0014	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CD—lung cancer	6.6e-05	0.00139	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—PIK3CA—lung cancer	6.53e-05	0.00138	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—KRAS—lung cancer	6.46e-05	0.00136	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—PIK3CA—lung cancer	5.93e-05	0.00125	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MDM2—lung cancer	5.91e-05	0.00125	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—RAF1—lung cancer	5.89e-05	0.00124	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—ERBB2—lung cancer	5.83e-05	0.00123	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CB—lung cancer	5.75e-05	0.00121	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MTOR—lung cancer	5.75e-05	0.00121	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CXCL8—lung cancer	5.53e-05	0.00117	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—HRAS—lung cancer	5.49e-05	0.00116	CbGpPWpGaD
Degarelix—GNRHR—GPCR downstream signaling—AKT1—lung cancer	5.34e-05	0.00113	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CASP3—lung cancer	5.29e-05	0.00112	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL2—lung cancer	5.28e-05	0.00111	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—IL6—lung cancer	5.25e-05	0.00111	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CCND1—lung cancer	5.15e-05	0.00109	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—JUN—lung cancer	5.14e-05	0.00108	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MMP9—lung cancer	5e-05	0.00105	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—CDKN1A—lung cancer	4.98e-05	0.00105	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PTEN—lung cancer	4.97e-05	0.00105	CbGpPWpGaD
Degarelix—GNRHR—Signaling by GPCR—AKT1—lung cancer	4.85e-05	0.00102	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EP300—lung cancer	4.74e-05	0.001	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—SRC—lung cancer	4.61e-05	0.000972	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—VEGFA—lung cancer	4.49e-05	0.000947	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—STAT3—lung cancer	4.44e-05	0.000938	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—NRAS—lung cancer	4.43e-05	0.000935	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MAPK3—lung cancer	4.25e-05	0.000896	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—MYC—lung cancer	4.13e-05	0.000871	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—EGFR—lung cancer	4.04e-05	0.000852	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—KRAS—lung cancer	3.82e-05	0.000805	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—PIK3CA—lung cancer	3.51e-05	0.00074	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—TP53—lung cancer	3.39e-05	0.000716	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—HRAS—lung cancer	3.24e-05	0.000684	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—IL6—lung cancer	3.1e-05	0.000655	CbGpPWpGaD
Degarelix—GNRHR—Signaling Pathways—AKT1—lung cancer	2.86e-05	0.000604	CbGpPWpGaD
